Pathlight
Pathlight

Our Team

Never losing sight of our guiding purpose to empower treatment decisions with greater insight and confidence.

Leadership Team

Roopom Banerjee

Executive Chairman
More
Linkedin-in

Brian Dow

Chief Financial Officer
More
Linkedin-in

Wendy Levin MD, MS

Chief Clinical Officer
More
Linkedin-in

Vicki Fish, MS, MBA

SVP Strategic Marketing
More
Linkedin-in

Taryn Cranford, PhD

VP Precision Medicine
More
Linkedin-in

Brenton Foretich

VP Clinical Operations
More
Linkedin-in

Christina Garcia

VP Compliance
More
Linkedin-in

Brian Krueger, PhD

VP Technology Development
More
Linkedin-in

Mark Landers

SVP Biopharma Partnerships
More
Linkedin-in

Board

Roopom Banerjee

Executive Chairman
Linkedin-in

Carl Barrett

Non-Executive Director
Linkedin-in

Roger Gunnarsson

Non-Executive Director
Linkedin-in

Ramez Sousou

Non-Executive Director

Ziad Essa

Non-Executive Director

Susanna Francke Rodau

Non-Executive Director
Linkedin-in

Join #TeamSAGA

Join our accomplished team. SAGA combines world-class genomic expertise with a leadership team deeply experienced in molecular residual disease (MRD), all aligned around a compelling vision of intercepting cancer at the earliest stages when it’s most treatable.

Open roles
SAGA Diagnostics

Roopom Banerjee

Executive Chairman
Linkedin-in

Roopom Banerjee is Executive Chairman at SAGA Diagnostics.

Roopom has 25+ years of experience in corporate strategy, investment banking, growth equity investments, company formation, and executive/board leadership. Roopom is currently a Senior Advisor at Bain Capital and Operating Partner at CRG Investments, as well as a Board Member for several life science companies. Previously, he was President and CEO at RainDance Technologies, which pioneered the first clinical tests and platforms utilizing Digital PCR, as well as the leading genomic platforms for inherited cancer testing. In his prior Wall Street experience, Roopom worked at Goldman Sachs, McKinsey and Leerink. His early career started in cancer genomics at the Massachusetts General Hospital, Dana Farber Cancer Institute, and Whitehead Institute Human Genome Project. Roopom holds three degrees from MIT and Harvard, was a former Howard Hughes Medical Institute (HHMI) Scholar, and voted one of Boston Business Journal’s “40 Under 40” award recipients.

Roopom holds degrees from MIT and Harvard.

Close

Brian Dow

Chief Financial Officer
Linkedin-in

Brian Dow is Chief Financial Officer at SAGA Diagnostics.

Brian joined SAGA Diagnostics in February 2024 as Chief Financial Officer and oversees the Company’s financial operations and serves as a member of the Executive Leadership Team. Brian is a senior financial executive with over 30 years of experience leading financial operations for both U.S. and international organizations. He joined SAGA Diagnostics from ProSomnus Sleep Technologies, a multi-national medical device company, where he held the role of Chief Financial Officer.

Earlier in his career Brian has held executive financial roles at Agendia N.V., Pulse Biosciences, Pacific Biosciences, and Northstar Neuroscience. Prior to this Brian had 14 years of increasing responsibilities in financial management of publicly traded companies and in public accounting as a manager with Ernst and Young. He is recognized as a licensed Certified Public Accountant by the Washington State Board of Accountancy and holds a Bachelor of Science in Management from the Georgia Institute of Technology.

Close

Wendy Levin MD, MS

Chief Clinical Officer
Linkedin-in

Wendy Levin in Chief Clinical Officer at SAGA Diagnostics.

Dr. Wendy Levin is a Hematologist and Oncologist with more than 15 years of increasing leadership experience in the biotech and diagnostic industries, spanning a broad range of disease indications, diagnostic targets, and early to late phase clinical development.

She has provided strategic and executional support for private pre-IPO start-ups to Fortune 500 publicly traded companies and investment firms, leading regulatory interactions, clinical advisory boards and global clinical and biomarker translational leadership for all phases of therapeutic development.

Wendy’s first role in biopharma was at Pfizer, where she led the translational and clinical development of Daurismo from pre-IND to designing the FDA registration trial in elderly unfit acute myeloid leukemia (AML) at Pfizer. She subsequently served as vice president and acting CMO of two small publicly traded companies, where she led clinical development and Medical Affairs, and served as the Global Clinical Lead for the $250M RP3 immuno-oncology DANUBE trial in 1L urothelial cancer, published in Lancet Oncology.

Most recently, she served as CMO for Biofidelity, a start-up clinical stage diagnostics company based in the UK. Wendy has considerable experience in both the buy and sell sides of VC, where she has conducted clinical due diligence for 10+ VC firms and has secured over $100M in capital, bringing novel therapeutics and practice-changing diagnostics to market.

Close

Vicki Fish, MS, MBA

SVP Strategic Marketing
Linkedin-in

Vicki Fish is the Senior Vice President of Strategic Marketing at SAGA Diagnostics, where she oversees global marketing strategy, portfolio positioning, and commercialization initiatives across the company’s precision oncology and molecular residual disease (MRD) platforms. Ms. Fish brings more than 25 years of experience driving market adoption, brand development, and revenue growth for advanced molecular diagnostics in oncology and complex genetic testing.

Prior to joining SAGA, Ms. Fish served as Vice President, Skin Cancer Marketing at Castle Biosciences, where she led strategic planning and execution for Castle’s dermatologic diagnostics portfolio. Previously, she was Vice President, Marketing at Natera, where she directed the launch and market expansion of the organ health product line in transplant and renal genetics. Earlier in her career, she spent over two decades at Myriad Genetics in progressive commercial leadership roles, most recently as Vice President, Dermatology, where she led the development, launch, and commercial scaling of MyPath® Melanoma — an innovative gene expression profile test.

Ms. Fish holds a B.A. in Biology from the University of Texas at Austin, an M.S. in Genetics from the University of North Texas, and an MBA from the University of Utah. She is actively involved in life sciences leadership development and previously served on the Development Committee for the University of Utah’s David Eccles School of Business Life Science MBA program, as well as the board of the David Eccles School of Business Alumni Network.

Close

Taryn Cranford, PhD

VP Precision Medicine
Linkedin-in

Taryn Cranford is VP Precision Medicine at SAGA Diagnostics.

Taryn comes to SAGA with more than 13 years of experience in the oncology research and clinical testing space, originating as a cellular and molecular scientist studying the immune response in hormone positive and triple negative breast cancer. After a postdoctoral fellowship in breast cancer genetics, she transitioned to industry working to optimize anatomical pathology and histology workflows to increase diagnostic efficiencies for Leica Biosystems. Realizing she could leverage this technical experience in sales, she achieved great success selling entire workflow solutions to clinical pathology labs with the aim to decrease diagnostic timelines.

Approached by Caris Life Sciences when they were creating a precision medicine team, Taryn pioneered a pathology focused sales approach that brought together clinicians from across the cancer care continuum. Her work aligned oncology, tissue acquisition, and pathology on clinical molecular testing workflows to decrease the overall time to patient treatment. Her elaborate understanding of complex systems and ability to drive collaboration drove industry changes in comprehensive molecular profiling. As the VP of Strategic Accounts at Caris, Taryn used her scientific and clinical expertise to drive systemic changes at top academic and community provider sites across the country.

Taryn serves as the VP of Precision Medicine at SAGA Diagnostics focusing to harmonize the commercial sales initiatives and SAGA’s clinical lab operations. This leverages her technical knowledge and precision medicine understanding with her strategic sales experience allowing for key customer expansion.

Close

Brenton Foretich

VP Clinical Operations
Linkedin-in

Brenton Foretich is VP Clinical Operations at SAGA Diagnostics.

Prior to joining, he worked in senior clinical operations, regulatory affairs and quality roles at Guardant Health, Georgetown Lombardi Comprehensive Cancer Center and Response Genetics. He also worked as a Clinical Operations and Quality Assurance consultant specialising in oncology clinical trials.

Brenton has expertise in companion diagnostics (CDx) for IVD manufacturing and CLIA labs.

Brenton has a BS, Chemical Engineering, Business Administration from University of Southern California.

Close

Christina Garcia

VP Compliance
Linkedin-in

Christina Garcia is VP Compliance at SAGA Diagnostics.

With over 18 years of experience in the life sciences industry, Christina has led compliance and privacy programs for medical device and laboratory companies, ensuring alignment with applicable laws, regulations, and industry guidance. Christina holds certifications in healthcare compliance, privacy, and ethics, and has a strong track record in program implementation, risk mitigation, auditing, and investigation. Her focus is on enhancing operational efficiency and maintaining regulatory alignment while fostering a culture of integrity and accountability that supports ethical innovation and patient trust throughout the healthcare ecosystem.

Close

Brian Krueger, PhD

VP Technology Development
Linkedin-in

Brian Krueger is VP of Technology Development and oversees SAGA’s Bioinformatics, Assay R&D, Applications and High-Throughput Automation groups.

Brian has extensive experience in high-throughput genomics, molecular diagnostics, and laboratory automation from his roles at Labcorp, Everly Health, Columbia University, Duke University, and the University of Florida. At Labcorp, he led the development and national deployment of the company’s COVID-19 RT-PCR test and created the NGS CORE platform to support highly scalable high-throughput sequencing assays. Earlier in his career, Brian established a viral genetics core facility at UF, modernized genome sequencing operations at Duke and at Columbia he built their biobanking, sequencing, informatics, and IT infrastructure from the ground up, enabling large-scale clinical genomics and research programs. Brian holds a PhD in Molecular and Cellular Biology from the University of Iowa.

Close

Mark Landers

SVP Biopharma Partnerships
Linkedin-in

Mark Landers leads Biopharma Partnerships at SAGA Diagnostics.

Mark joined the team in August of 2025 as Senior Vice President of Biopharma Partnerships focused on creating strategic value through partnerships with pharma and biotech. With over 25 years experience in oncology diagnostics and genomics, Mark has led the development, deployment and commercialization of multiple diagnostic tests and precision medicine initiatives. Most recently he led Precision Medicine at Akoya Biosciences and has held leadership roles at Exact Sciences, Guardant Health and Epic Sciences.

Earlier in his career he led R&D and new product launches at AltheaDx, Life Technologies, Ceregene and Vical. He holds a Bachelor of Science in Microbiology from San Diego State University.

Close